Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Income towards Parent Company (2023 - 2025)

Mangoceuticals' Income towards Parent Company history spans 3 years, with the latest figure at -$2.8 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 42.12% to -$2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$20.6 million, a 137.08% decrease, with the full-year FY2025 number at -$20.6 million, down 137.08% from a year prior.
  • Income towards Parent Company hit -$2.8 million in Q4 2025 for Mangoceuticals, up from -$7.6 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for MGRX hit a ceiling of -$1.8 million in Q3 2023 and a floor of -$7.6 million in Q3 2025.
  • Historically, Income towards Parent Company has averaged -$3.2 million across 3 years, with a median of -$2.5 million in 2023.
  • Biggest five-year swings in Income towards Parent Company: grew 24.12% in 2024 and later tumbled 281.0% in 2025.
  • Tracing MGRX's Income towards Parent Company over 3 years: stood at -$2.6 million in 2023, then grew by 24.12% to -$1.9 million in 2024, then tumbled by 42.12% to -$2.8 million in 2025.
  • Business Quant data shows Income towards Parent Company for MGRX at -$2.8 million in Q4 2025, -$7.6 million in Q3 2025, and -$5.4 million in Q2 2025.